Antihypertensive drug

Source: Wikipedia, the free encyclopedia.
(Redirected from
Antihypertensive
)

Antihypertensives are a class of

angiotensin II receptor antagonists (ARBs), and beta blockers
.

Which type of medication to use initially for hypertension has been the subject of several large studies and resulting national guidelines. The fundamental goal of treatment should be the prevention of the important

NICE in the UK for those under 55 years old.[6]

Diuretics

Hydrochlorothiazide, a popular thiazide diuretic

Diuretics help the kidneys eliminate excess salt and water from the body's tissues and blood.

In the United States, the JNC8 (Eighth Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) recommends thiazide-type diuretics to be one of the first-line drug treatments for hypertension, either as monotherapy or in combination with

combination drugs, such as ACE inhibitor and thiazide combinations. Despite thiazides being cheap and effective, they are not prescribed as often as some newer drugs. This is because they have been associated with increased risk of new-onset diabetes and as such are recommended for use in patients over 65, for whom the risk of new-onset diabetes is outweighed by the benefits of controlling systolic blood pressure.[8] Another theory is that they are off-patent and thus rarely promoted by the drug industry.[9]

Medications that are classified as potassium-sparing diuretics which block the epithelial sodium channel (ENaC), such as amiloride and triamterene, are seldom prescribed as monotherapy. ENaC blocker medications need stronger public evidence for their blood pressure reducing effect.[10]

Calcium channel blockers

Calcium channel blockers block the entry of calcium into muscle cells in artery walls, resulting in the relaxation of muscle cells and vasodilation.[11][12]

The 8th Joint National Committee (JNC-8) recommends calcium channel blockers to be a first-line treatment either as monotherapy or in combination with

angiotensin II receptor antagonists for all patients regardless of age or race.[7]

The ratio of CCBs' anti-proteinuria effect, non-dihydropyridine to dihydropyridine was 30 to −2.[13] The anti-proteinuria effect of non-dihydropyridine is due to better selectivity during glomerular filtration and/or a lower perfusion rate through the renal system.[14]

Notable side effects of CCBs include edema, flushing in the face, headache, drowsiness, and dizziness.[14]

ACE inhibitors

Captopril, the prototypical ACE inhibitor

vasoconstrictor.[15]

A systematic review of 63 trials with over 35,000 participants indicated ACE inhibitors significantly reduced doubling of serum creatinine levels compared to other drugs (ARBs, α blockers, β blockers, etc.), and the authors suggested this as a first line of defense.

beta blockers.[17] As such, ACE inhibitors should be the drug treatment of choice for patients with chronic kidney disease regardless of race or diabetic status.[7]

However, ACE inhibitors (and angiotensin II receptor antagonists) should not be a first-line treatment for black hypertensives without

combination drugs, such as ACE inhibitor and thiazide combinations.[20]

Notable side effects of ACE inhibitors include

dry cough, high blood levels of potassium, fatigue, dizziness, headaches, loss of taste and a risk for angioedema.[21]

Angiotensin II receptor antagonists

Valsartan, an angiotensin II receptor antagonist

angiotensin receptors.[22]

In 2004, an article in the

BMJ examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of myocardial infarction (heart attack).[23] The matter was debated in 2006 in the medical journal of the American Heart Association. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.[24][25]

In the VALUE trial, the angiotensin II receptor blocker valsartan produced a statistically significant 19% (p=0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with amlodipine.[26]

The CHARM-alternative trial showed a significant +52% (p=0.025) increase in myocardial infarction with candesartan (versus placebo) despite a reduction in blood pressure.[27]

As a consequence of AT1 blockade, ARBs increase angiotensin II levels several-fold above baseline by uncoupling a

negative-feedback loop. Increased levels of circulating Angiotensin II result in unopposed stimulation of the AT2 receptors, which are, in addition upregulated. Recent data suggest that AT2 receptor stimulation may be less beneficial than previously proposed and may even be harmful under certain circumstances through mediation of growth promotion, fibrosis, and hypertrophy, as well as proatherogenic and proinflammatory effects.[28][29][30]

ARBs happens to be the favorable alternative to ACE inhibitors if the hypertensive patients with the heart failure type of reduced ejection fraction treated with ACEis was intolerant of cough, angioedema other than hyperkalemia or chronic kidney disease.[31][32][33]

Adrenergic receptor antagonists

Propranolol, the first beta-blocker to be successfully developed

Beta-blockers can block beta-1 adrenergic receptors and/or beta-2 adrenergic receptors. Those that block beta-1-adrenergic receptors prevent the binding of endogenous catecholamines (such as epinephrine and norepinephrine), which ultimately reduces blood pressure through decreasing renin and cardiac output release. Those that block beta-2-adrenergic receptors reduce blood pressure through increased relaxation of smooth muscle. [34]

Alpha-blockers can block alpha-1 adrenergic receptors and/or alpha-2 adrenergic receptors.[35] Those that block alpha-1-adrenergic receptors on vascular smooth muscle cells prevent vasoconstriction.[35] Blockade of alpha-2-adrenergic receptors prevents the negative feedback mechanism of norepinephrine (NE).[35] Non-selective alpha-blockers generate a balance whereby alpha-2-blockers release NE to reduce the vasodilation effects induced by alpha-1-blockers.[35]

Although

National Institute for Health and Clinical Excellence, downgraded the role of beta-blockers due to their risk of provoking type 2 diabetes.[40]

Despite lowering blood pressure, alpha blockers have significantly poorer endpoint outcomes than other antihypertensives, and are no longer recommended as a first-line choice in the treatment of hypertension.[41] However, they may be useful for some men with symptoms of prostate disease.

Vasodilators

Vasodilators act directly on the smooth muscle of arteries to relax their walls so blood can move more easily through them; they are only used in hypertensive emergencies or when other drugs have failed, and even so are rarely given alone.[42]

malignant hypertension or aortic dissection).[43][44] Hydralazine and its derivatives are also used in the treatment of severe hypertension, although they should be avoided in emergencies.[44] They are no longer indicated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in gestational hypertension.[43]

Renin inhibitors

Renin comes one level higher than angiotensin converting enzyme (ACE) in the renin–angiotensin system. Renin inhibitors can therefore effectively reduce hypertension. Aliskiren (developed by Novartis) is a renin inhibitor which has been approved by the U.S. FDA for the treatment of hypertension.[45]

Aldosterone receptor antagonist

Aldosterone receptor antagonists, also known as mineralocorticoid receptor antagonist (MRA) can lower blood pressure by blocking the binding of aldosterone to the mineralocorticoid receptor. Spironolactone and eplerenone are MRAs that causes a block in the reabsorption of sodium, resulting in a decrease in blood pressure.[46][47]

Aldosterone receptor antagonists are not recommended as first-line agents for blood pressure,[48] but spironolactone and eplerenone are both used in the treatment of heart failure and resistant hypertension.

Alpha-2 adrenergic receptor agonists

Central alpha agonists lower blood pressure by stimulating alpha-receptors in the brain which open peripheral arteries easing blood flow. These

autoreceptors
which provide negative feedback in neurotransmission (in this case, the vasoconstriction effects of adrenaline). Central alpha agonists, such as clonidine, are usually prescribed when all other anti-hypertensive medications have failed. For treating hypertension, these drugs are usually administered in combination with a diuretic.

Adverse effects of this class of drugs include sedation, drying of the nasal mucosa and rebound hypertension upon discontinuation.[49]

Some indirect anti-adrenergics are rarely used in treatment-resistant hypertension:

  • guanethidine – replaces norepinephrine in vesicles, decreasing its tonic release
  • antinicotinic
    and ganglion blocker
  • VMAT
    inhibition

For the most resistant and severe disease, oral minoxidil (Loniten) in combination with a diuretic and β-blocker or other sympathetic nervous system suppressants may be used.[medical citation needed]

Endothelium receptor blockers

Bosentan belongs to a new class of drugs and works by blocking endothelin receptors. It is specifically indicated only for the treatment of pulmonary artery hypertension in patients with moderate to severe heart failure.[50]

Choice of initial medication

For mild blood pressure elevation, consensus guidelines call for medically supervised lifestyle changes and observation before recommending initiation of drug therapy. However, according to the American Hypertension Association, evidence of sustained damage to the body may be present even prior to observed elevation of blood pressure. Therefore, the use of hypertensive medications may be started in individuals with apparent normal blood pressures but who show evidence of hypertension-related nephropathy, proteinuria, atherosclerotic vascular disease, as well as other evidence of hypertension-related organ damage.

If lifestyle changes are ineffective, then drug therapy is initiated, often requiring more than one agent to effectively lower hypertension. Which type of many medications should be used initially for hypertension has been the subject of several large studies and various national guidelines. Considerations include factors such as age, race, and other medical conditions.

angiotensin II receptor antagonists.[7]

The first large study to show a mortality benefit from antihypertensive treatment was the VA-NHLBI study, which found that chlorthalidone was effective.[51] The largest study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002, concluded that chlorthalidone (a thiazide-like diuretic) was as effective as lisinopril (an angiotensin converting enzyme inhibitor) or amlodipine (a calcium channel blocker).[18] (ALLHAT showed that doxazosin, an alpha-adrenergic receptor blocker, had a higher incidence of heart failure events, and the doxazosin arm of the study was stopped.)

A subsequent smaller study (ANBP2) did not show the slight advantages in thiazide diuretic outcomes observed in the ALLHAT study, and actually showed slightly better outcomes for ACE-inhibitors in older white male patients.[52]

Thiazide diuretics are effective, recommended as the best first-line drug for hypertension,

Chlorthalidone is the thiazide drug that is most strongly supported by the evidence as providing a mortality benefit; in the ALLHAT study, a chlorthalidone dose of 12.5 mg was used, with titration up to 25 mg for those subjects who did not achieve blood pressure control at 12.5 mg. Chlorthalidone has repeatedly been found to have a stronger effect on lowering blood pressure than hydrochlorothiazide, and hydrochlorothiazide and chlorthalidone have a similar risk of hypokalemia and other adverse effects at the usual doses prescribed in routine clinical practice.[54] Patients with an exaggerated hypokalemic response to a low dose of a thiazide diuretic should be suspected to have hyperaldosteronism, a common cause of secondary hypertension.[55]

Other medications have a role in treating hypertension. Adverse effects of thiazide diuretics include

diabetes mellitus type 2. The thiazide diuretics also deplete circulating potassium unless combined with a potassium-sparing diuretic or supplemental potassium. Some authors have challenged thiazides as first line treatment.[56][57][58] However, as the Merck Manual of Geriatrics notes, "thiazide-type diuretics are especially safe and effective in the elderly."[59]

Current UK guidelines suggest starting patients over the age of 55 years and all those of African/Afrocaribbean ethnicity firstly on calcium channel blockers or thiazide diuretics, whilst younger patients of other

ethnic groups should be started on ACE-inhibitors. Subsequently, if dual therapy is required to use ACE-inhibitor in combination with either a calcium channel blocker or a (thiazide) diuretic. Triple therapy is then of all three groups and should the need arise then to add in a fourth agent, to consider either a further diuretic (e.g. spironolactone or furosemide), an alpha-blocker or a beta-blocker.[60] Prior to the demotion of beta-blockers as first line agents, the UK sequence of combination therapy used the first letter of the drug classes and was known as the "ABCD rule".[60][61]

Patient factors

The choice between the drugs is to a large degree determined by the characteristics of the patient being prescribed for, the drugs' side effects, and cost. Most drugs have other uses; sometimes the presence of other symptoms can warrant the use of one particular antihypertensive. Examples include:

The JNC8 guidelines indicate reasons to choose one drug over the others for certain individual patients.[7]

Antihypertensive Medication during the First Trimester of Pregnancy

Hypertensive disorders during pregnancy constitute a significant risk factor for maternal and fetal outcomes, necessitating antihypertensive treatment. However, current data concerning the safety of in utero exposure to antihypertensive medication are controversial. While some studies recommend the administration of certain agents, others underline the possible adverse effects on fetal development. In general, a-methyldopa, β-blockers and calcium channel blockers are the first or second treatment line for hypertension during pregnancy. However, ACEIs, ARBs and diuretics are mostly contraindicated, as the potential risk outweighs the benefits of their administration. Additionally, several drugs should be avoided, due to the lack of data regarding their safety.[70] Women are often concerned about the safety of antihypertensives and as a result, many do not take their treatment as prescribed. Shared decision-making aids have been shown to reduce women's uncertainty about taking antihypertensives and increase the number of women taking them as prescribed.[71][72]

History

History of Thiazides

Chlorothiazide was discovered in 1957, but the first known instance of an effective antihypertensive treatment was in 1947 using primaquine, an antimalarial.[73]

History of Calcium Channel Blockers

In 1883, Ringer discovered the involvement of calcium for cellular activity on isolated heart.[74] Later in 1901, Stiles reported the same activity in muscle contraction.[74] In the early 1940s, Kamada (from Japan) and Heilbrunn (from the United States) noted how calcium was involved with muscle contractions.[74] In 1964, calcium channel blockers were discovered in Godfraind’s laboratory through the screening of coronary dilators, which showed how calcium was blocked from entering artery cells, resulting in vasorelaxation.[74]

Research

Blood pressure vaccines

Vaccinations are being trialed and may become a treatment option for high blood pressure in the future. CYT006-AngQb was only moderately successful in studies, but similar vaccines are being investigated.[75]

Anti-hypertensive drugs in older people

The latest evidence does not have evidence of an effect due to discontinuing vs continuing medications used for treating elevated blood pressure or prevention of heart disease in older adults on all-case mortality and incidence of heart attack.[76] The findings are based on low quality evidence suggesting it may be safe to stop anti-hypertensive medications. However, older adults should not stop any of their medications without talking to a healthcare professional.[76]

References

  1. ^ Antihypertensive+Agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
  2. PMID 14604498
    .
  3. ^ a b Nelson M. "Drug treatment of elevated blood pressure". Australian Prescriber (33): 108–112. Archived from the original on 26 August 2010. Retrieved August 11, 2010.
  4. S2CID 204078909
    .
  5. PMID 29667175
    .
  6. ^ "Hypertension: Management of hypertension in adults in primary care | Guidance | NICE" (PDF). 28 June 2006. Archived (PDF) from the original on 2012-01-07. Retrieved 2012-01-09., p19
  7. ^
    PMID 24352797
    .
  8. PMID 16801488
    .
  9. PMID 10209012
    .
  10. PMID 23152254
    .
  11. PMID 21896151
    .
  12. PMID 31643892
    . Retrieved 2023-12-22.
  13. PMID 15149313
    .
  14. ^
    PMID 21896151
    .
  15. ISBN 978-0-12-369400-3
    . Retrieved 2024-03-13.
  16. ^
    PMID 24157497
    .
  17. ^
    PMID 12435255
    .
  18. ^
    PMID 12479763
    .
  19. PMID 16864749
    .
  20. S2CID 222320206
    .
  21. ^ "High blood pressure (hypertension) - Uses for ACE inhibitors". Mayo Clinic. Archived from the original on 2016-08-01. Retrieved 2016-07-27. Page updated: June 29, 2016
  22. PMID 16278727
    .
  23. PMID 15564232
    .
  24. PMID 16923768
    .
  25. PMID 16923769
    .
  26. ^ Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. (June 2004). "Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial". Lancet. 363 (9426): 2022–31.
    S2CID 19111421
    .
  27. ^ Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. (September 2003). "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial". Lancet. 362 (9386): 772–6.
    S2CID 5650345
    .
  28. ^ Levy BI (September 2005). "How to explain the differences between renin angiotensin system modulators". American Journal of Hypertension. 18 (9 Pt 2): 134S–141S.
    PMID 16125050
    .
  29. ^ Lévy BI (January 2004). "Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system". Circulation. 109 (1): 8–13.
    PMID 14707017
    .
  30. ^ Reudelhuber TL (December 2005). "The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous". Hypertension. 46 (6): 1261–2.
    PMID 16286568
    .
  31. PMID 2057034
    .
  32. PMID 27208050
    .
  33. PMID 25148386
    .
  34. PMID 30422501
    , retrieved 2024-01-21
  35. ^
    PMID 32310526
    . Retrieved 2024-01-21.
  36. S2CID 34364430
    .
  37. S2CID 23759357
    .
  38. PMID 10381708
    .
  39. National Institute for Health and Clinical Excellence. Archived from the original
    (PDF) on 2007-02-16. Retrieved 2006-09-30.
  40. National Institute for Health and Clinical Excellence. Archived from the original
    on 2007-09-29. Retrieved 2006-09-30.
  41. PMID 12925554
    .
  42. PMID 32119310
    . Retrieved 2024-03-16.
  43. ^
    ISBN 978-0-07-144343-2
    .
  44. ^
    PMID 10893382
    .
  45. ^ Mehta A (January 1, 2011). "Direct Renin Inhibitors as Antihypertensive Drugs". Archived from the original on 21 February 2014. Retrieved 6 February 2014.
  46. PMID 16200104
    .
  47. PMID 32119308
    . Retrieved 2024-03-16.
  48. ^
    PMID 12748199
    .
  49. PMID 25849473
    .
  50. PMID 19688101
    .
  51. S2CID 40939559
    .
  52. PMID 12584366
    .
  53. S2CID 53207044
    .
  54. ^ Watson K (18 May 2016). "Which Thiazide-Type Diuretic Should be First-Line in Patients with Hypertension?". University of Maryland School of Pharmacy.
  55. ^ Oiseth S, Jones L, Maza E (eds.). "Hyperaldosteronism". The Lecturio Medical Concept Library. Retrieved 25 July 2021.
  56. S2CID 20976708
    .
  57. S2CID 43027989
    .
  58. S2CID 26414121
    .
  59. ^ "Section 11. Cardiovascular Disorders – Chapter 85. Hypertension". Merck Manual of Geriatrics. July 2005. Archived from the original on 2009-01-23.
  60. ^
    National Institute for Health and Clinical Excellence. 28 June 2006. Archived from the original
    (PDF) on 13 March 2009. Retrieved 2009-03-04.
  61. PMID 14594956
    .
  62. PMID 28439398
    .
  63. S2CID 145847997
    .
  64. PMID 27527376
    .
  65. S2CID 20842819
    .
  66. PMID 20818905
    .
  67. PMID 12748199. Archived
    (PDF) from the original on 2013-02-16. Retrieved 2013-02-17.
  68. PMID 17502569
    .
  69. PMID 30540406
    .
  70. S2CID 246826268
    .
  71. S2CID 257843687
    .
  72. S2CID 252414448
    .
  73. ^ Freis ED (1995). "Historical Development of Antihypertensive Treatment" (PDF). In Laragh JM, Brenner BM (eds.). Hyperlension: Pathophysiology, Diagnosis, and Management (Second ed.). New York: Raven Press, Ltd. pp. 2741–5. Archived from the original (PDF) on 2017-02-22.
  74. ^
    PMID 28611661
    .
  75. S2CID 15949
    .
  76. ^
    PMID 32519776
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Antihypertensive_drug&oldid=1216053747"